{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:32:40Z","timestamp":1789813960277,"version":"4.0.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.jacl.2015.01.001","type":"journal-article","created":{"date-parts":[[2015,1,14]],"date-time":"2015-01-14T01:38:46Z","timestamp":1421199526000},"page":"170-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Understanding PCSK9 and anti-PCSK9 therapies"],"prefix":"10.1016","volume":"9","author":[{"given":"James M.","family":"McKenney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2015.01.001_bib1","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacl.2015.01.001_bib2","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein LDL) receptor and LDL cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2015.01.001_bib3","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nsmb1235","article-title":"Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia","volume":"14","author":"Cunningham","year":"2007","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.jacl.2015.01.001_bib4","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","article-title":"PCSK9: A key modulator of cardiovascular health","volume":"114","author":"Seidah","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.jacl.2015.01.001_bib5","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role of mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jacl.2015.01.001_bib6","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacl.2015.01.001_bib7","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1194\/jlr.M003566","article-title":"Strong induction of PCSKi9 gene expression through HNF1alpha and SREBP2: mechanisms for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters","volume":"51","author":"Dong","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2015.01.001_bib8","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1194\/jlr.M700443-JLR200","article-title":"Sterol-dependent regulation of proprotein convertase subtilisin\/kexin type 9 expression by sterol-regulatory element binding protein-2","volume":"49","author":"Jeong","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2015.01.001_bib9","doi-asserted-by":"crossref","first-page":"28885","DOI":"10.1074\/jbc.M109.052407","article-title":"Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine","volume":"284","author":"Li","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2015.01.001_bib10","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of pro-protein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation","volume":"282","author":"Zhang","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2015.01.001_bib11","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1074\/jbc.M808363200","article-title":"Structural and biochemical characterization of the wild type PCSK9\/EGF (AB) complex and natural familial hypercholesterolemia mutants","volume":"284","author":"Bottomley","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2015.01.001_bib12","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/embor.2011.205","article-title":"Mechanistic implications for LDL receptor degradation from the PCSK9\/LDLR structure at neutral pH","volume":"12","author":"Surdo","year":"2011","journal-title":"EMBO Rep"},{"key":"10.1016\/j.jacl.2015.01.001_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2015.01.001_bib14","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia\u2014the MENDEL-2 randomized, controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"JACC"},{"key":"10.1016\/j.jacl.2015.01.001_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-511X-7-22","article-title":"Plasma PCSK9 levels are significantly modified by statins and fibrates in humans","volume":"7","author":"Mayne","year":"2008","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.jacl.2015.01.001_bib16","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1194\/jlr.M700437-JLR200","article-title":"Atorvastatin increases human serum levels of proprotein convertase subtilisin\/kexin type 9","volume":"49","author":"Careskey","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2015.01.001_bib17","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1194\/jlr.M008144","article-title":"High- dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol","volume":"51","author":"Welder","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2015.01.001_bib18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1373\/clinchem.2011.172932","article-title":"Rosuvastatin, proprotein convertase subtilisin\/kexin 9 concentrations, and LDL cholesterol response : the JUPITER trial","volume":"58","author":"Awan","year":"2012","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2015.01.001_bib19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1194\/jlr.M900273-JLR200","article-title":"A new method of measurement of total plasma PCSK9: clinical applications","volume":"51","author":"Dubuc","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2015.01.001_bib20","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.01.001_bib21","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"JACC"},{"key":"10.1016\/j.jacl.2015.01.001_bib22","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.01.001_bib23","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1093\/hmg\/ddr578","article-title":"Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification","volume":"21","author":"Tveten","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jacl.2015.01.001_bib24","doi-asserted-by":"crossref","first-page":"28856","DOI":"10.1074\/jbc.M109.037085","article-title":"Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route","volume":"284","author":"Poirier","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2015.01.001_bib25","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2015.01.001_bib26","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1194\/jlr.M800027-JLR200","article-title":"Plasma PCSK9 preferentially reduces liver receptors in mice","volume":"49","author":"Grefhorst","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2015.01.001_bib27","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1194\/jlr.M800542-JLR200","article-title":"Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice","volume":"50","author":"Luo","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2015.01.001_bib28","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1194\/jlr.M006635","article-title":"PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain","volume":"51","author":"Liu","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2015.01.001_bib29","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1194\/jlr.M014118","article-title":"PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke","volume":"52","author":"Rousselet","year":"2011","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2015.01.001_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2008.06.010","article-title":"Molecular basis of PCSK9 function","volume":"203","author":"Lambert","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.01.001_bib31","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.numecd.2011.06.002","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): from structure:function relation to therapeutic inhibition","volume":"21","author":"Tibolla","year":"2011","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jacl.2015.01.001_bib32","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2015.01.001_bib33","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/ATVBAHA.110.214130","article-title":"Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans","volume":"30","author":"Persson","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2015.01.001_bib34","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.atherosclerosis.2007.07.022","article-title":"Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa","volume":"196","author":"Homer","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.01.001_bib35","doi-asserted-by":"crossref","first-page":"10561","DOI":"10.1074\/jbc.M808802200","article-title":"Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells","volume":"284","author":"McNutt","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2015.01.001_bib36","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1194\/jlr.M800049-JLR200","article-title":"Functional analysis of sites within PCSK9 responsible for hypercholesterolemia","volume":"49","author":"Pandit","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2015.01.001_bib37","first-page":"1135","article-title":"The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol","volume":"7","author":"Poirier","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jacl.2015.01.001_bib38","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1136\/jmg.2006.038356","article-title":"Genetic causes of familial hypercholesterolemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk","volume":"43","author":"Humphries","year":"2006","journal-title":"J Med Genet"},{"key":"10.1016\/j.jacl.2015.01.001_bib39","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variation in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"NEJM"},{"key":"10.1016\/j.jacl.2015.01.001_bib40","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","article-title":"The C676X mutation in PCSK9 is present and lowers cholesterol in a southern African population","volume":"193","author":"Amanda","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2015.01.001_bib41","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1161\/ATVBAHA.109.194191","article-title":"PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia","volume":"29","author":"Cariou","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2015.01.001_bib42","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characteristics of loss-of-function mutations in PCSK9 and identification of compound heterozygote","volume":"79","author":"Zhao","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jacl.2015.01.001_bib43","doi-asserted-by":"crossref","first-page":"15502","DOI":"10.1073\/pnas.95.26.15502","article-title":"RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans","volume":"95","author":"Montgomery","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacl.2015.01.001_bib44","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.01.001_bib45","unstructured":"Available at: clinicaltrials.gov. Accessed March 12, 2015."},{"key":"10.1016\/j.jacl.2015.01.001_bib46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/138920021503140412212905","article-title":"Biologics: an update and challenge of their pharmacokinetics","volume":"15","author":"Shi","year":"2014","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.jacl.2015.01.001_bib47","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"Roth","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.01.001_bib48","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.01.001_bib49","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/humu.1380010602","article-title":"Molecular genetics of the LDL receptor gene in familial hypercholesterolemia","volume":"1","author":"Hobbs","year":"1992","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jacl.2015.01.001_bib50","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.01.001_bib51","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","author":"Raal","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.01.001_bib52","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","author":"Raal","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.01.001_bib53","doi-asserted-by":"crossref","unstructured":"Kastelein JJP, Ginsberg HN, Langslet G, et\u00a0al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolaemia (heFH) not adequately controlled with current lipid-lowering therapy: results of ODYSSEY FH I and FH II studies. Presented at the European Society of Cardiology Congress 2014, Barcelona (August 30, 2014).","DOI":"10.1007\/s10557-014-6523-z"},{"key":"10.1016\/j.jacl.2015.01.001_bib54","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2015.01.001_bib55","unstructured":"Moriarty PM, Thompson PD, Cannon CP, et\u00a0al. ODYSSEY ALTERNATIVE: Efficacy and safety of alirocumab versus ezetimibe, in patients with statin intolerance defined by placebo run-in and statin rechallenge arm. Presented at the American Heart Association Scientific Session 2014, Chicago (Nov 20, 2014)."},{"key":"10.1016\/j.jacl.2015.01.001_bib56","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2015.01.001_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with suboptimally controlled hypercholesterolemia on maximally tolerated doses of statins: the ODYSSEY COMBO I study","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2015.01.001_bib58","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2015.01.001_bib59","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2015.01.001_bib60","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2015.01.001_bib61","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.01.001_bib62","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.amjcard.2003.08.009","article-title":"Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia","volume":"92","author":"Stein","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2015.01.001_bib63","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2015.01.001_bib64","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1185\/030079903125002405","article-title":"Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial","volume":"19","author":"McKenney","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacl.2015.01.001_bib65","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.01.001_bib66","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2015.01.001_bib67","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.113.007012","article-title":"Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial","volume":"129","author":"Koren","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2015.01.001_bib68","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1194\/jlr.R300002-JLR200","article-title":"Familial hypobetalipoproteinemia: a review","volume":"44","author":"Schonfeld","year":"2003","journal-title":"J Lipid Res"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415000021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287415000021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T19:44:13Z","timestamp":1651002253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287415000021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S1933287415000021"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2015.01.001","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding PCSK9 and anti-PCSK9 therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2015.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 National Lipid Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}